Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in...
-
Upload
bernard-shaw -
Category
Documents
-
view
217 -
download
0
Transcript of Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in...
![Page 1: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/1.jpg)
Its not over after day 100:Studying Late Effects of
Hematopoietic Cell TransplantationThriving in the long run
Daniel Weisdorf, MD
October, 2011
thanks to Linda Burns,Stephanie Lee, Navneet Majhail
![Page 2: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/2.jpg)
One Survivor’s History: Nearly the whole storyAllo
sib HCT
97 98 99 00 01 02 03 04 05 06
Tongue dysplasia
LRD renal tx
Esophageal strictures
AVN hip
Vertebral compression fractures
Hip arthroplasty
Hypogonadism
Herpes zoster
Osteoporosis
Renal insufficiency
Secondary hyperparathyroidism
Chronic GVHD mouth, GI tract, skin ---
HTN
Cataracts Lipid panel
![Page 3: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/3.jpg)
Overview
• What is the problem• Recommended screening and preventive practices –
Organ problems & Second Cancers– Joint Recommendations of the EBMT, CIBMTR, ASBMT
(Rizzo et al BBMT 2006; 12:136)– Update being submitted for publication
• Prospective trial challenges– Specific organ problems– Guides for Health Screening– BMT Survivors’ Study
![Page 4: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/4.jpg)
Leaving the Transplant Center
![Page 5: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/5.jpg)
Challenges in studying Late effects
• The problem….Too many issues
Incidence & risk factors not well defined
Patients are remote from HCT center
Chronic morbidity; not acute
Less pressing than cancer or GVHD
So it gets less attention
HCT oncologists may not be eager 1o care docs
![Page 6: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/6.jpg)
How big is the Problem?
• 30,000-40,000 transplants each year • Increasing number of patients cured
• Sequelae cause substantial morbidity• Optimizing outcomes requires:
– Prevention– Early detection of complications– Mitigation of disability
![Page 7: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/7.jpg)
Non-HCT related co-morbidities
Relapse
Getting older concernsTransplant long-term effects
Transplant late effects
It’s a big puzzle
![Page 8: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/8.jpg)
What are the Problems?Several categories
•Later onset medical problems
eyes, bones, fertility, thyroid, dental etc
•Risk factors for later or progressive injury to
heart, kidneys, liver
metabolic, vascular, viral
•2nd cancers
![Page 9: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/9.jpg)
What are other Problems?
•Later manifestations of peri-HCT illness
Neurocognitive
Psychiatric
Lungs
![Page 10: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/10.jpg)
Good care can limit morbidity
• Screen for the signs/symptoms– H&P, Labs, Imaging– Educate patients for self-screening
• Screen for the risk factors– Metabolic syndrome -- cardiovascular– Subclinical -- early intervention
![Page 11: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/11.jpg)
Identifying the problems
• Early detection– 2nd cancers
– Who should get screening
![Page 12: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/12.jpg)
Late mortality: in 2 year disease free survivors
Bhatia, Blood, 2007
![Page 13: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/13.jpg)
Late causes of death (2 yr)
Socie et al, NEJM 1999Bhatia et al, Blood 2007
Median age at HCT: 26 yearsMost received marrow from HLA-id siblings
Chronic GVHD 25%
Infection 7%
Secondary ca 7%
Organ failure 7%Other 4%
Relapse 50%
25% of late deaths
![Page 14: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/14.jpg)
Late causes of death (5 yr)
Martin P, JCO 2010
Median age at HCT: ~ 32 yearsMost received marrow from HLA-id siblingsN=2160, 286 deaths
Chronic GVHD 11%
Infection 17%
Secondary ca 28%Cardiovasc 10%
Respiratory 7%
Other 9%
Unknown 4%
Relapse 14%
75% of really late deaths
![Page 15: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/15.jpg)
Chronic health conditions in 2 year disease-free survivors
Sun CL et al, Blood 2010
N=1022 HLA-ID sibMedian FU 7.3 yrs
Gr 3-5 illnesses 35% at 10 y
![Page 16: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/16.jpg)
Any Chronic health conditions: 10 year survivors
Kersey, Sun CL et al, ASH 2011
N=366 survivors + 306 sibsMedian FU 15 yrs (10-28) 70% @15 yrs; 40% severe/life threatening
![Page 17: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/17.jpg)
Healthy Behaviors: Survivors vs. Sibs
![Page 18: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/18.jpg)
Survivors not better at screening--mammograms
Armenian, BMT, 2011
![Page 19: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/19.jpg)
Survivors slightly better at trying to stay healthy
Armenian, BMT, 2011
![Page 20: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/20.jpg)
It’s no longer a question of staying healthy.
It’s a question of finding a sickness you like.
-Jackie Mason
![Page 21: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/21.jpg)
TBI Immunosuppressants,Chronic GVHD and Steroids
Immune deficiencyChronic GVHD
Late infections
Chemotherapy
Major Risk Factors
Fertility, hypogonadismGrowth and developmentThyroid dysfunctionDental diseaseCataractsSecond malignancies
Neurocognitive dysfunctionSicca syndromeOsteoporosisOsteonecrosisLung dysfunctionIron overload
LATE EFFECTS
![Page 22: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/22.jpg)
Psychosocial Adjustment
• 65% report fatigue and sleeping disorders
• 25% problems with intimacy
• Occupational disability
• Depression in patient and caregivers
Recommendation: High vigilance, minimal screening every 6 months
![Page 23: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/23.jpg)
Adverse Psychological Outcomes: Survivors vs. their Sibs
CL Sun et al, 2011
![Page 24: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/24.jpg)
Adverse Psychological Outcomes: Survivors: Improvements over tme
CL Sun et al, 2011
![Page 25: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/25.jpg)
Nervous System
• 20% impaired memory, attention/verbal fluency
• Calcineurin-induced CNS toxicity
• Leukoencephalopathy
• Peripheral neuropathy– Chemotherapy– cGVHD
![Page 26: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/26.jpg)
Cataracts and TBI
Benyunes et al. Int J Radiat Oncol Biol Phys 1995;32:661.
![Page 27: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/27.jpg)
Oral Complications
Secondary to TBI and cGHVD– Decreased saliva production– Intra-oral malignancies (cGHVD)– Increased risk of dental caries
Recommendations: Dental evaluation at 6-12 months post transplant: caries, adequacy of saliva production, dental hygiene, ? fluoride treatments
![Page 28: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/28.jpg)
Endocrine Abnormalities
• Thyroid dysfunction– Subclinical-compensated hypothyroidism– Overt hypothyroidism– Autoimmune thyroid disease
• Hypoadrenalism• Growth retardation/delayed puberty• Fertility/hypogonadism
Recommendations: Yearly screening of thyroid function; annual gynecologic/endocrine assessment for women and in men per symptoms; consider hormone replacement
![Page 29: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/29.jpg)
Pulmonary Late Effects
• 15-40% of patients• Factors:
– cytoxic agents – irradiation – infections– immune-mediated lung injury
• Restrictive lung disease• Chronic obstructive lung disease
Recommendations: Controversial – screen at one year (allo HCT) or by symptoms
![Page 30: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/30.jpg)
HepatitisProspective EBMT study in “post screening” era
HBsAg (%) HCV-RNA (%)
SCT recipients 3.1 6.0
“de novo” infections 2.0 7.4
Positive donors 2.6 3.6
Recommendation: LFTs yearly, monitor viral load, liver bx in HCV
Locasciulli A et al. Transplantation 1994:14:833
![Page 31: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/31.jpg)
Renal
• True incidence of end-stage disease unknown
• Glomerulonephritis, nephrotic syndrome• Dysfunction related to chemotherapy,
TBI, age, antimicrobials, immunosuppressants
![Page 32: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/32.jpg)
Metabolic Syndrome
![Page 33: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/33.jpg)
Metabolic Syndrome
• Transplant at City of Hope or U of MN 1974-1998• HCT = 1276; siblings 383• Survived ≥2 yrs post transplant• Median age at transplant = 32.9 yrs• Median f/u = 7.1 yrs
Baker KS et al, 2005
![Page 34: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/34.jpg)
Compared with their siblings, allo HCT survivors were:
• 4.1 x more likely to report diabetes
• 2.3 x more likely to report hypertension
• 7.9 x more likely to report stroke
There were no differences in auto HCT survivors and their siblings
![Page 35: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/35.jpg)
Osteonecrosis
• Total dose/duration of steroids and TBI are risk factors
• Mean time from transplant 18 months• MRI required for diagnosis• Sites
- Hip 80%
- Knee 10%
Recommendation: Screening is not recommended; perform MRI if symptomatic
![Page 36: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/36.jpg)
Osteoporosis
Characterized by reduced bone mass and increased susceptibility to fracture
Normal Osteoporosis
![Page 37: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/37.jpg)
Bone Loss in HCT
• Varying degrees in up to 50% of adult pts after allo HCT
• Conflicting data in auto HCT (females at greater risk)
• Greatest bone loss in first 6 months
![Page 38: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/38.jpg)
Factors Predisposing to Bone Loss
• Glucocorticoid– decreases in bone formation and vit D3 concentration
• Cyclosporine/tacrolimus• Hypogonadism• TBI• Hypomagnesemia• Reduced physical activity• Direct effect of GVHD on bone cells• Abnormal cytokine-mediated bone turnover• G-CSF
![Page 39: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/39.jpg)
Second Malignancies• 3372 consecutive patients• 1974 - 2001• Malignant (78%) and non-malignant diseases• Median age 24 years (range 0.1-67)• Auto (35%), MRD (42%), URD (23%)• 78% received TBI containing prep
• Median f/u = 5 yrs (range 0.5-25)• Person years of f/u = 10,494 years
Baker et al. J Clin Onc 2003;21:1352
![Page 40: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/40.jpg)
Second Malignancies
• 147 post-transplant malignancies/137 pts
• 8.1 fold increased risk
• Increased risk for MDS/AML, NHL/PTLPD, HL, and solid tumors
• Solid tumors – melanoma, brain, oral
![Page 41: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/41.jpg)
Second Malignancies
Baker et al. J Clin Onc 2003;21:1352
![Page 42: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/42.jpg)
0
1
2
3
4
5
6
7
8
9
10
0 1 2 3 4 5 6 7YEARS SINCE TRANSPLANT
CU
MU
LAT
IVE
IN
CID
EN
CE
(%
)
NHLn=37 HD
n=19
8.1%± 2.9%at 7 yrs
NHL+HD: 2,733 pts 56 cases
N at risk:
2,733 1,832 1,275 883 567 331 191 84
MDS after autografting Pre HCT factors are important Higher risks with: extended alkylator, More TBI, PBSC
Metayer, Blood, 2003
![Page 43: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/43.jpg)
![Page 44: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/44.jpg)
Challenges to Care & Study of Late Effects
• Impending shortage of physicians
• Oncologists are not interested in PCP role
• Shared care model common & communication often difficult
• Randomized studies suggest non-oncologists can provide quality survivorship care for solid tumor survivors
![Page 45: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/45.jpg)
Family Physicians vs. Specialists
• Multi-center study (N=968) of early stage breast cancer 9-15 months after adjuvant treatment
• Randomized to follow-up care with their own family physician vs. oncologist
• No differences– recurrent disease (11.2% vs. 13.2%)– deaths (6% vs. 6.2%)– serious clinical events (3.5% vs. 3.7%)
Grunfeld E et al, JCO 2006
![Page 46: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/46.jpg)
Survivorship Care Plan – Part 1
• Comprehensive treatment summary– Cancer type, extent– Treatment(s) – Potential complications
IOM 2005; “From Cancer Patient to Cancer Survivor:Lost in Transition”
![Page 47: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/47.jpg)
• Risk-based follow-up care plan– Planned schedule for screening: cancer
recurrence & treatment complications– Teachable moment: General and
cancer-specific preventive practices– Employment, insurance issues– Psychosocial screening and support– Provider assignments
Survivorship Care Plan – Part 2
![Page 48: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/48.jpg)
Continuing Obstacles to Study
Still limited literature—Registry observational studies
Late complications—low incidence
Limited by recall, bias and followup
![Page 49: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/49.jpg)
Continuing Obstacles to Study
Prospective studies need to be:Large and thus expensive
Study lots of detail in a few orFew details in many
If f/u interventions are important, then center practices may matter
![Page 50: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/50.jpg)
Continuing Obstacles to Study
Are late effects from HCT or from pre-HCT therapy
Do comorbidities which preclude HCT select out those at lesser risk for late effects?
Will liberalizing the age & comorbidity eligibility for HCT alter the incidence and severity of late effects?
![Page 51: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/51.jpg)
Continuing Obstacles to Study
Aging of survivors
of investigators of methods for study
Should we use electronic f/u Social media for symptom recording
Design the longterm followapp
![Page 52: Its not over after day 100: Studying Late Effects of Hematopoietic Cell Transplantation Thriving in the long run Daniel Weisdorf, MD October, 2011 thanks.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649e055503460f94af1c56/html5/thumbnails/52.jpg)
BMT CLINIC